Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis
- PMID: 20883364
- DOI: 10.1111/j.1346-8138.2010.00883.x
Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis
Abstract
Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology which presents immunological, vascular and connective tissue abnormalities. Serum interleukin (IL)-6 has been reported to be elevated in patients with SSc. Clinical and laboratory findings affecting the elevated level of high-sensitivity C-reactive protein (hs-CRP) were studied in patients with SSc. Clinical and laboratory findings also included serum IL-6 level. Thirty-nine SSc patients (male : female = 7:32, age 19-84 years, mean 62.6 years) were studied. hs-CRP was measured with a nephelometric assay. Serum IL-6 level was measured by enzyme-linked immunosorbent assay. The distributions of hs-CRP showed that 18 cases (46.2%) were not elevated (<0.07 mg/dL), but 21 cases (53.8%) were (≥0.07 mg/dL). Alkaline phosphatase and IL-6 in SSc patients with elevated hs-CRP (291 ± 95 U/L, 3.23 ± 2.74 pg/mL) were significantly more elevated than those in not elevated patients (221 ± 75 U/L, 1.53 ± 1.12 pg/mL) (P < 0.02, P < 0.01). The correlation between hs-CRP level and IL-6 level in SSc patients was 0.687 (P < 0.001). In conclusion, elevated serum IL-6 levels are reflected in elevated hs-CRP levels in SSc patients.
© 2010 Japanese Dermatological Association.
Similar articles
-
Relation between elevated high-sensitivity C-reactive protein and anti-mitochondria antibody in patients with systemic sclerosis.J Dermatol. 2008 Feb;35(2):70-5. doi: 10.1111/j.1346-8138.2008.00418.x. J Dermatol. 2008. PMID: 18271801
-
Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.J Rheumatol. 1997 Feb;24(2):328-32. J Rheumatol. 1997. PMID: 9034992
-
Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.Arthritis Care Res (Hoboken). 2012 Sep;64(9):1405-14. doi: 10.1002/acr.21716. Arthritis Care Res (Hoboken). 2012. PMID: 22556030
-
IL-18 is involved in vascular injury in end-stage renal disease patients.Nephrol Dial Transplant. 2009 Feb;24(2):589-96. doi: 10.1093/ndt/gfn486. Epub 2008 Sep 4. Nephrol Dial Transplant. 2009. PMID: 18775894
-
The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.Mod Rheumatol. 2019 Mar;29(2):294-301. doi: 10.1080/14397595.2018.1559909. Epub 2019 Feb 6. Mod Rheumatol. 2019. PMID: 30561237 Review.
Cited by
-
Bank1 and NF-kappaB as key regulators in anti-nucleolar antibody development.PLoS One. 2018 Jul 17;13(7):e0199979. doi: 10.1371/journal.pone.0199979. eCollection 2018. PLoS One. 2018. PMID: 30016332 Free PMC article.
-
Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.J Clin Med. 2022 Apr 20;11(9):2299. doi: 10.3390/jcm11092299. J Clin Med. 2022. PMID: 35566425 Free PMC article. Review.
-
Circulating biomarkers of interstitial lung disease in systemic sclerosis.Int J Rheumatol. 2012;2012:121439. doi: 10.1155/2012/121439. Epub 2012 Sep 3. Int J Rheumatol. 2012. PMID: 22988462 Free PMC article.
-
Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis.Cells. 2021 Dec 2;10(12):3402. doi: 10.3390/cells10123402. Cells. 2021. PMID: 34943909 Free PMC article. Review.
-
Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis.Postepy Dermatol Alergol. 2020 Dec;37(6):921-926. doi: 10.5114/ada.2019.84746. Epub 2019 Apr 26. Postepy Dermatol Alergol. 2020. PMID: 33603610 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous